Want to see JP:4597 full AI Analyst Report?
Top Page
Solasia Pharma KK
(4597)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥29.00
▲(7.41% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance—large ongoing losses and sustained negative operating/free cash flow—despite low leverage. Technicals are supportive with the stock trading above major moving averages and positive MACD, but elevated RSI/Stoch indicate extended momentum. Valuation is a secondary drag because negative earnings (negative P/E) limit confidence in earnings-based pricing, and no dividend yield is available.
Positive Factors
Low Leverage
Very low leverage limits near-term interest and refinancing pressure, giving Solasia greater financial flexibility while it funds oncology development and works toward improving commercial performance.
Negative Factors
Persistent Cash Burn
Sustained operating and free-cash-flow deficits indicate that the business is not self-funding. Continued development spending may require additional financing, creating dilution or funding risk if cash burn persists.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits near-term interest and refinancing pressure, giving Solasia greater financial flexibility while it funds oncology development and works toward improving commercial performance.
Read all positive factors
Solasia Pharma KK (4597) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.92B
Dividend YieldN/A
Average Volume (3M)41.98M
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth32.42%
EPS Growth61.00%
CountryJP
Employees22
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.33
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Solasia Pharma KK Business Overview & Revenue Model
Company Description
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil...
How the Company Makes Money
null...
Solasia Pharma KK Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 388.00M | 429.00M | 316.00M | 617.00M | 1.09B | 559.00M |
| Gross Profit | 158.00M | 171.00M | -10.00M | -163.00M | 128.00M | -121.00M |
| EBITDA | -855.00M | -822.00M | -796.00M | -639.00M | -1.20B | -1.92B |
| Net Income | -900.00M | -876.00M | -1.94B | -1.11B | -2.55B | -2.48B |
Balance Sheet | ||||||
| Total Assets | 1.90B | 2.15B | 1.36B | 2.55B | 3.56B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.39B | 886.00M | 728.00M | 803.00M | 714.00M |
| Total Debt | 78.00M | 159.00M | 25.00M | 60.00M | 37.00M | 84.00M |
| Total Liabilities | 443.00M | 392.00M | 203.00M | 673.00M | 899.00M | 1.17B |
| Stockholders Equity | 1.45B | 1.75B | 1.16B | 1.88B | 2.66B | 2.59B |
Cash Flow | ||||||
| Free Cash Flow | -1.14B | -847.00M | -1.03B | -359.00M | -2.07B | -2.48B |
| Operating Cash Flow | -1.14B | -847.00M | -1.03B | -359.00M | -2.07B | -2.47B |
| Investing Cash Flow | -114.00M | -81.00M | 0.00 | 2.00M | -418.00M | -164.00M |
| Financing Cash Flow | 995.00M | 1.43B | 1.18B | 275.00M | 2.57B | 361.00M |
Solasia Pharma KK Technical Analysis
Negative
27.00
Price Trends
27.80
Positive
28.88
Positive
29.99
Negative
Market Momentum
0.93
Positive
46.39
Neutral
9.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4597, the sentiment is Negative. The current price of 27 is below the 20-day moving average (MA) of 30.75, below the 50-day MA of 27.80, and below the 200-day MA of 29.99, indicating a neutral trend. The MACD of 0.93 indicates Positive momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 9.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4597.
Solasia Pharma KK Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ¥13.52B | 19.58 | ― | ― | 13.30% | 66.38% | |
54 Neutral | ¥5.70B | -45.84 | ― | 3.21% | 0.60% | -131.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥7.92B | -8.71 | -54.56% | ― | 32.42% | 61.00% | |
44 Neutral | ¥4.97B | -0.62 | ― | ― | -37.69% | 1.85% | |
44 Neutral | ¥5.66B | -7.00 | ― | ― | 364.72% | 18.43% | |
41 Neutral | ¥3.44B | -1.37 | ― | ― | ― | -5.66% |
* Healthcare Sector Average
JP:4597
Solasia Pharma KK
29.00
-8.00
-21.62%
JP:4539
Nippon Chemiphar Co., Ltd.
1,574.00
3.84
0.24%
JP:4574
Taiko Pharmaceutical Co., Ltd.
268.00
-37.00
-12.13%
JP:4582
Symbio Pharmaceuticals Limited
62.00
-86.00
-58.11%
JP:4883
Modalis Therapeutics Corporation
33.00
-54.00
-62.07%
JP:4892
Cyfuse Biomedical K.K.
570.00
-52.00
-8.36%
Solasia Pharma KK Corporate Events
Solasia Pharma Advances Oncology Portfolio With Partner Shifts and Global Expansion
Aug 13, 2026
Solasia Pharma reported its second-quarter update for the fiscal year ending December 31, 2026, highlighting progress across its marketed products and development pipeline in oncology and supportive care. The company is also advancing several earl...
Solasia Pharma Widens Mid-Year Loss and Scraps Full-Year Forecast Amid Revenue Slump
Aug 13, 2026
Solasia Pharma reported consolidated sales of ¥8 million for the six months ended June 30, 2026, an 82.5% year-on-year decline, and an operating loss of ¥570 million, leaving net profit attributable to owners of the parent at a loss of &...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.